Literature DB >> 19152151

Optimizing in vitro conditions for immunomodulation and expansion of mesenchymal stromal cells.

H Samuelsson1, O Ringdén, H Lönnies, K Le Blanc.   

Abstract

BACKGROUND AIMS: Mesenchymal stromal cells (MSC) can be expanded in vitro for clinical use and have been evaluated in clinical trials as immunosuppressants and to heal damaged tissues. We investigated the impact of freezing and prolonged storage on cell viability, proliferation and immunosuppression in vitro.
METHODS: MSC were expanded from bone marrow (BM) of healthy subjects according to standard protocols in the presence of fetal calf serum (FCS). The immunosuppressive potential of MSC was analyzed in mixed lymphocyte cultures (MLC) and after stimulation with phytohemagglutinin (PHA).
RESULTS: Expansion of frozen mononuclear cells (MNC) diminished MSC yield after expansion compared with plating of fresh MNC. MSC derived from frozen MNC were also less immunosuppressive. MSC harvested at various passages after expansion in vivo suppressed lymphocyte proliferation equally. Pooling of MSC from several donors generated higher and more stable suppression in both MLC and after PHA stimulation. After passage 1, plating at lower densities in 20% FCS increased cell expansion of MSC up to 25-fold compared with standard conditions.
CONCLUSIONS: MNC should not be frozen prior to MSC expansion. Decreased replating density and increased FCS levels generate higher numbers of MSC. Freezing of ex vivo-expanded MSC for >30 months did not affect cell viability or the ability to suppress lymphocyte proliferation. For effective immunosuppression in vitro MSC should be stored for less than 6 months and pooled from two or three donors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19152151     DOI: 10.1080/14653240802684194

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  23 in total

1.  Recent Patents Pertaining to Immune Modulation and Musculoskeletal Regeneration with Wharton's Jelly Cells.

Authors:  Limin Wang; Mark L Weiss; Michael S Detamore
Journal:  Recent Pat Regen Med       Date:  2013

2.  Effects of perfusion and cyclic compression on in vitro tissue engineered meniscus implants.

Authors:  M Petri; K Ufer; I Toma; C Becher; E Liodakis; S Brand; P Haas; C Liu; B Richter; C Haasper; G von Lewinski; M Jagodzinski
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2011-07-13       Impact factor: 4.342

Review 3.  Mesenchymal stem cell transplantation in multiple sclerosis.

Authors:  Jeffrey A Cohen
Journal:  J Neurol Sci       Date:  2013-01-04       Impact factor: 3.181

4.  Immunosuppression of allogenic mesenchymal stem cells transplantation after spinal cord injury improves graft survival and beneficial outcomes.

Authors:  Abel Torres-Espín; Elena Redondo-Castro; Joaquim Hernandez; Xavier Navarro
Journal:  J Neurotrauma       Date:  2015-01-22       Impact factor: 5.269

5.  Evaluating Effect of Mesenchymal Stem Cells on Expression of TLR2 and TLR4 in Mouse DCs.

Authors:  Mohammad Hossein Karimi; Zahra Barzkar; Maryam Babaee; Majid Naghdi
Journal:  Adv Pharm Bull       Date:  2016-06-30

6.  Mesenchymal stem cells: From bench to bedside.

Authors:  Teng Ma
Journal:  World J Stem Cells       Date:  2010-04-26       Impact factor: 5.326

Review 7.  Mesenchymal stromal cells: a new tool against graft-versus-host disease?

Authors:  Frédéric Baron; Rainer Storb
Journal:  Biol Blood Marrow Transplant       Date:  2011-09-29       Impact factor: 5.742

8.  Mesenchymal stromal cells from pooled mononuclear cells of multiple bone marrow donors as rescue therapy in pediatric severe steroid-refractory graft-versus-host disease: a multicenter survey.

Authors:  Zyrafete Kuçi; Halvard Bönig; Hermann Kreyenberg; Milica Bunos; Anna Jauch; Johannes W G Janssen; Marijana Škifić; Kristina Michel; Ben Eising; Giovanna Lucchini; Shahrzad Bakhtiar; Johann Greil; Peter Lang; Oliver Basu; Irene von Luettichau; Ansgar Schulz; Karl-Walter Sykora; Andrea Jarisch; Jan Soerensen; Emilia Salzmann-Manrique; Erhard Seifried; Thomas Klingebiel; Peter Bader; Selim Kuçi
Journal:  Haematologica       Date:  2016-05-12       Impact factor: 9.941

9.  Do cryopreserved mesenchymal stromal cells display impaired immunomodulatory and therapeutic properties?

Authors:  Guido Moll; Jessica J Alm; Lindsay C Davies; Lena von Bahr; Nina Heldring; Lillemor Stenbeck-Funke; Osama A Hamad; Robin Hinsch; Lech Ignatowicz; Matthew Locke; Helena Lönnies; John D Lambris; Yuji Teramura; Kristina Nilsson-Ekdahl; Bo Nilsson; Katarina Le Blanc
Journal:  Stem Cells       Date:  2014-09       Impact factor: 6.277

10.  Fibroblasts and Mesenchymal Stromal/Stem Cells Are Phenotypically Indistinguishable.

Authors:  Ryan A Denu; Steven Nemcek; Debra D Bloom; A Daisy Goodrich; Jaehyup Kim; Deane F Mosher; Peiman Hematti
Journal:  Acta Haematol       Date:  2016-05-18       Impact factor: 2.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.